详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

出处：

DOI：

关键词： abiraterone acetate exosomes messenger prostatic neoplasms RNA TUBB3

摘要：

To use ddPCR to quantify plasma exosomal class III β-tubulin (βIII-tubulin, TUBB3, encoded by the TUBB3 gene) mRNA expression in metastatic castration-resistant prostate cancer (mCRPC) patients, and study the association of this expression with abiraterone efficacy.Blood samples were prospectively collected from 52 mCRPC patients using abiraterone as first-line therapy to measure plasma exosomal TUBB3 mRNA expression value before the initiation of abiraterone. Study endpoints were PSA response rate, PSA-progression-free survival (PSA-PFS), and overall survival (OS, from CRPC to death).Patients with positive exosomal TUBB3 expression showed shorter PSA-PFS (negative TUBB3 vs. positive TUBB3: 11.0 vs. 7.9 months; p = 0.014). Further analysis demonstrated that patients with strongly positive exosomal TUBB3 (>20 copies/20 µl) was associated with even shorter PSA-PFS (negative TUBB3 vs. positive TUBB3 [<20 copies/20 µl] vs. strongly positive TUBB3 [>20 copies/20 µl]: 11.0 vs. 8.3 vs. 3.6 months, p = 0.005). In multivariate analyzes, TUBB3 (+) (HR: 2.114, p = 0.033) and ECOG score >2 (HR: 3.039, p = 0.006) were independent prognosticators of poor PSA-PFS. PSA response and OS did not present significant differences.The exosomal TUBB3 mRNA expression level is associated with poor PSA-PFS of abiraterone in mCRPC patients. The detection of exosomal TUBB3 can be valuable in their management.© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone. [2]A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy naive patients with mCRPC in China, Malaysia, Thailand and Russia [3]A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia [4]Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. [5]Prospects for the clinical application of exosomal circular RNA in squamous cell carcinoma [6]Exosomal RNA-profiling of pleural effusions identifies adenocarcinoma patients through elevated miR-200 and LCN2 expression [7]The optimal core number and site for MRI-targeted biopsy of prostate? A systematic review and pooled analysis. [8]Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer. [9]Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study. [10]FSH Is Responsible for Androgen Deprivation Therapy-Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion